Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative

Tine Cuppens, Daniela Annibali, An Coosemans, Jone Trovik, Natalja ter Haar, Eva Colas, Angel Garcia-Jimenez, Koen Van de Vijver, Roy P. M. Kruitwagen, Mariel Brinkhuis, Michal Zikan, Pavel Dundr, Jutta Huvila, Olli Carpen, Johannes Haybaeck, Farid Moinfar, Helga B. Salvesen, Maciej Stukan, Carole Mestdagh, Ronald P. ZweemerLeonardus F. Massuger, Michael R. Mallmann, Eva Wardelmann, Miriam Mints, Godelieve Verbist, Debby Thomas, Ellen Gomme, Els Hermans, Philippe Moerman, Tjalling Bosse, Frederic Amant*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1274-1285
Number of pages12
JournalClinical Cancer Research
Volume23
Issue number5
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • ENDOMETRIAL STROMAL SARCOMA
  • SOFT-TISSUE SARCOMA
  • GROWTH-FACTOR RECEPTOR
  • AKT-MTOR PATHWAY
  • MAMMALIAN TARGET
  • BREAST-CANCER
  • CYCLIN D1
  • EXPRESSION
  • TUMORS
  • TRIAL

Cite this